Co-administration of a water-soluble polymer increases the usefulness of cyclodextrins in solid oral dosage forms

Pharmaceutical Research

Volumn 15, Issue 11, 1998, Pages 1696-1701

  Savolainen, Jouko ^a   Järvinen, Kristiina ^a   Taipale, Hannu ^a   Jarho, Pekka ^a   Loftsson, Thorsteinn ^b   Järvinen, Tomi ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF ICELAND   (Iceland)

Author keywords

Bioavailability; Cyclodextrins; Glibenclamide; Hydroxypropylmethylcellulose; Oral administration

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BETA CYCLODEXTRIN; BETA CYCLODEXTRIN SULFOBUTYL ETHER; CYCLODEXTRIN DERIVATIVE; GLIBENCLAMIDE; POLYMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SOLUBILIZATION; TABLET FORMULATION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CYCLODEXTRINS; DOGS; DOSAGE FORMS; GLYBURIDE; HYDROGEN-ION CONCENTRATION; INJECTIONS, INTRAVENOUS; MALE; POLYMERS; SOLUBILITY; WATER;

EID: 0031786697     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011900527021     Document Type: Article

References (26)

1. th edition, The Pharmaceutical Press, London, 1989, pp. 389.
2. L. Groop, E. Wåhlin-Boll, K.-J. Tötterman, A. Melander, E.-M. Tolppanen, and F. Fyhrqvist. Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetes. Eur. J. Clin. Pharmacol. 28:697-704 (1985).
3. J. B. Chalk, M. Patterson, M. T. Smith, and M. J. Eadie. Correlations between in vitro dissolution, in vivo bioavailability and hypoglycaemic effect of oral glibenclamide. Eur. J. Clin. Pharmacol. 31:177-182 (1986).
4. O. Shaheen, S. Othman, I. Jalal, A. Awidi, and W. Al-Turk. Comparison of pharmacokinetics and pharmacodynamics of a conventional and a new rapidly dissolving glibenclamide preparation. Int. J. Pharm. 38:123-131 (1987).
5. M. T. Esclusa-Diaz, J. J. Torres-Labandeira, M. Kata, and J. L. Vila-Jato. Inclusion complexation of glibenclamide with 2-hydroxypropyl-β-cyclodextrin in solution and in solid state. Eur. J. Pharm. Sci. 1:291-296 (1994).
6. N. M. Sanghavi, H. Venkatesh, and V. Tandel. Solubilization of glibenclamide with β-cyclodextrin & its derivates. Drug Dev. Ind. Pharm. 20:1275-1283 (1994).
7. A. Mitrevej, N. Sinchaipanid, V. Junyaprasert, and L. Warintornuwat. Effect of grinding of β-cyclodextrin and glibenclamide on tablet properties. Part I. in vitro. Drug Dev. Ind. Pharm. 22:1237-1241 (1996).
8. A. Gerlóczy, M. Vikmon, J. Szemán L. Jicsinszky, D. Acerbi, P. Ventura, M. Pasini, and J. Szejtli. Absorption Studies on Glibenclamide/Sodium/ β-Cyclodextrin complex in Rabbits. In P. Couvreur, D. Duchêne, I. Kalles (eds.), Minutes of the Formulation of Poorly-available Drugs for Oral Administration, Editions de Santé, Paris, 1996, pp. 257-260.
9. V. J. Stella and R. A. Rajewski. Cyclodextrins: Their future in drug formulation and delivery. Pharm. Res. 14:556-567 (1997).
10. R. A. Rajewski and V. J. Stella. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J. Pharm. Sci. 85:1142-1169 (1996).
11. T. Loftsson, H. Fridriksdóttir, A. M. Sigurdadóttir, and H. Ueda. The effect of water-soluble polymers on drug-cyclodextrin complexation. Int. J. Pharm. 110:169-177 (1994).
12. T. Loftsson, H. Fridriksdóttir, and T. K. Gudmundsdóttir. The effect of water-soluble polymers on aqueous solubility of drugs. Int. J. Pharm. 127:293-296 (1996).
13. H. Fridriksdóttir, T. Loftsson, and E. Stefánsson. Formulation and testing of methazolamide cyclodextrin eye drop solutions. J. Contr. Rel. 44:95-99 (1997).
14. M. Gibaldi and D. Perrier. Pharmacokinetics, 2nd ed., Marcel Dekker Inc., New York, 1982.
15. T. Higughi and K. A. Connors. Phase-solubility techniques. Adv. Anal. Chem. Instr. 4:117-212 (1965).
16. D. O. Thompson. Cyclodextrins-Enabling Excipients: Their Present and Future Use in Pharmaceuticals. In S. Bruck (ed.), Crit. Rev. Ther. Drug Carr. Syst. 14:1-104 (1997).
17. M. D. Johnson, B. L. Hoesterey, and B. D. Anderson. Solubilization of a tripeptide HIV protease inhibitor using a combination of ionization and complexation with chemically modified cyclodextrins. J. Pharm. Sci. 83:1142-1146 (1994).
18. K. Okimoto, R. A. Rajewski, K. Uekama, J. A. Jona, and V. J. Stella. The interaction of charged and uncharged drugs with neutral (HP-β-CD) and anionically charged (SBE7-β-CD) β-cyclodextrins. Pharm. Res. 13:256-264 (1996).
19. T. Loftsson, T. K. Gudmundsdóttir, and H. Fridriksdóttir. The influence of water-soluble polymers and pH on hydroxypropyl-β-cyclodextrin complexation of drugs. Drug Dev. Ind. Pharm. 22:401-405 (1996).
20. L. S. Goodman and A. Gilman. The Pharmacological Basis of Therapeutics, Pergamon Press, New York, 1990.
21. K. Uekama, S. Narisawa, F. Hirayama and M. Otagiri. Improvement of dissolution and absorption characteristics of benzodiazepines by cyclodextrin complexation. Int. J. Pharm. 16:327-338 (1983).
22. T. Järvinen, K. Järvinen, N. Schwarting, and V. J. Stella, β-Cyclodextrin Derivatives, SBE4-β-CD and HP-β-CD, Increase the oral bioavailability of cinnarizine in beagle dogs. J. Pharm. Sci. 84:295-299 (1995).
23. C. J. Betlach, M. A. Gonzalez, B. C. McKiernan, C. Neff-Davis, and N. Bodor. Oral pharmacokinetics of carbamazepine in dogs from commercial tablets and a cyclodextrin complex. J. Pharm. Sci. 82:1058-1060 (1993).
24. M. E. Brewster, W. R. Anderson, D. Meinsma, D. Moreno, A. I. Webb, L. Pablo, K. S. Estes, H. Derendorf, N. Bodor, R. Sawchuk, B. Cheung, and E. Pop. Intravenous and oral pharmacokinetic evaluation of a 2-hydroxypropyl-β-cyclodextrin based formulation of carbamazepine in the dog: comparison with commercially available tablets and suspensions. J. Pharm. Sci. 86:335-339 (1997).
25. J. K. Kristinsson, H. Fridriksdóttir, S. Thórisdóttir, A. M. Sigurdardóttir, E. Stefánsson, and T. Loftsson. Dexamethasone-cyclodextrin-polymer co-complexes in aqueous eye drops. Invest. Ophthalmol. Vis. Sci. 37:1199-1203 (1996).
26. H. Fridriksdóttir, T. Loftsson, J. A. Gudmundsson, G. J. Bjarnason, M. Kjeld, and T. Thorsteinsson. Desing and in vivo testing of 17β-estradiol-HPβCD sublingual tablets. Pharmazie 51:39-42 (1996).